RVLP(Delisted)
RVL PharmaceuticalsยทNASDAQ
--
--(--)
RVLP Profile
Rvl Pharmaceuticals Plc
A specialty pharmaceutical company focused on commercializing the treatment of acquired blepharoptosis, or low-lying eyelid, in adults
400 Crossing Boulevard, Bridgewater, NJ 08807
--
RVL Pharmaceuticals plc was incorporated as a private limited company under the laws of Ireland on 13 July 2017. The Company is a specialty pharmaceutical company focused on the development and commercialization of products targeting underserved patient populations in ophthalmic medicine and medical aesthetic treatments. In July 2020, the company received FDA regulatory approval for RVL-1201, or Upneq (oxymetazoline hydrochloride eye drops), 0.1%, for the treatment of adult acquired ptosis, or ptosis or drooping eyelids.
